VEGFA and age-related macular degeneration: The purpose of this study was to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of 0.3 mg hI-con1 (ICON-1) administered as monotherapy and in combination with 0.5 mg anti-VEGF antibody ranibizumab (Lucentis, Genentech, South San Francisco, CA, USA) compared to ranibizumab 0.5 mg monotherapy in treating 88 patients with choroidal neovascularization (CNV) secondary to AMD.